Serum Institute to Produce 100 million COVID-19 Vaccines, price $3 per dose in India

COVID-19 vaccine: Serum Institute of India joined hands with the richest man, Bill Gates in lieu of making the delivery of coronavirus vaccine more feasible. To boost up the manufacturing of the vaccine and accelerate more than 100 million doses for India and other low-income countries of the world, Serum Institute of India joined hands with Bill & Melina Gates Foundation, Vaccine Alliance, and Gavi. this joined efforts will surely prove to be an amazing step towards the process of developing the vaccine and this could also lead to speed up of the process. As per the news SII will deliver up to 100 million doses of the COVID-19 vaccines for $3 (Rs 225 appx) a dose for India and low- and middle-income countries.

The Executive Officer of SII, in a statement, had announced that “The funding will be supported at-risk manufacturing vaccines by SII for the candidate vaccines from AstraZeneca and Novavax, which will be available for acquisition in case the institute is successful in attaining full licensure and as per the WHO prequalification,”

Adar Poonawalla’s Serum Institute of India has entered into agreements with many leading vaccine candidates in order to provide for an effective and efficient vaccine to the Indian public when the vaccine is finally out in the market after the final clinical trials. The SII signed this agreement on 30th July 2020.  

Under the agreement passed on 30th July 2020, the Serum Institute will be responsible for submitting the information to regulatory and marketing authorities while Novavax will provide both vaccine antigen and Matrix‐M adjuvant to the Serum Institute of India.

Both AstraZeneca and Novavax candidates are now in the final stages of clinical trials for the serum vaccination for COVID-19. Earlier Serum Institute of India hooked up with the Oxford University-AstraZeneca in the process of manufacturing COVID-19 vaccine in India. Later on, The Drug Controller General of India had provided a green signal to SII so that they could conduct human clinical trials for Phase-II and Phase-III for the candidates of Oxford-Astra Zeneca vaccine. Now Serum Institute of India has joined hands in order to make the delivery of the COVID-19 vaccine more feasible. 

Earlier this month, Novavax declared information regarding the speed of the vaccine concluding, that its vaccine candidates were generally well-tolerated and elicited numerically superior robust antibody responses to those seen in phase I and phase II studies of human convalescent sera for the vaccine tested on them.

Click Here to Register for Bank Exams 2020 Preparation Material

The Chief Executive officer of SII, Adar Poonawala speaks out while collaboration with Novavax that “We believe, Novavax’ NVX-CoV2373 has significant potential and capability to successfully prevent and treat COVID-19. As earlier we have successful experience with Novavax in regards to the development of a malaria vaccine, we have been familiar with the power of their vaccine technologies”. He ended up saying that “We would definitely like to work again together to bring this vaccine to Indian and other countries patients to lower the pandemic effect.”

Visit Achieversadda.com and participate in discussions with other aspirants and achievers. Get answers to your queries and connect with others on Achieversadda.com